Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Q1FY23 Quarterly Result Announced for Eris Lifesciences Ltd.

 Pharmaceuticals firm Eris Lifesciences Announced Q1FY23 Result : Zomelis Mother Brand hits a revenue run rate of Rs. 100 cr. p.a. in just 2.5 years of acquisition, representing a growth of more than 8x in monthly sales since acquisition Glimisave MV crosses a MAT revenue of Rs. 100 cr.; we expect to have a total of four Rs. 100+ crore brands by the end of FY23 including Zomelis, Glimisave M, Glimisave MV and Renerve Plus Oaknet business is off to a strong start in Q1 FY23 Total Revenue = Rs. 55 crore; Post-deal revenue for Eris = INR 31.5 cr Total EBIDTA = Rs. 10 crore in Q1; this run-rate looks sustainable through the year Executed an in-licensing agreement with Biocon for Glargine – expecting launch in Q3 FY23 Expecting stronger momentum in core cardio-metabolic business in subsequent quarters Sharp revival of the market in Jun-July 2022 (13% growth) After a 12-month period of slowdown (4% growth) from Jun-21 to May-22 Successfully executing on strategic objective of therapy diversification with 3 emerging therapies (Dermatology, CNS and Women’s Health) collectively accounting for 20% of Branded Formulations revenue and growing at > 25% p.a. FY 23 guidance (including Oaknet) Consolidated Revenue growth of 30% Consolidated EBIDTA growth of 16-17% Result PDF
05-08-2022
Bigul

Eris Lifesciences Ltd - 540596 - Corporate Action-Board approves Dividend

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e., 05 August 2022, inter alia, duly approved/took on record the following: ? Unaudited Standalone Financial Results and Unaudited Consolidated Financial Results for the quarter ended 30 June 2022; ? Declaration of interim dividend of Rs. 7.35/- (at the rate of 735%) on each fully paid-up equity share of Re. 1/- for the Financial Year 2022-2023; ? Further, as Communicated in our intimation letter dated 02 August 2022, the record date for determining the eligibility of shareholders for the payment of the interim dividend has been fixed as 16 August 2022. The payment of interim dividend would be made to the eligible shareholders on or before 04 September 2022. The Board Meeting commenced at 11:00 A.M. and concluded at 12:35 P.M. Kindly take the above information on your records.
05-08-2022
Bigul

Eris Lifesciences Ltd - 540596 - OUTCOME OF THE BOARD MEETING

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e., 05 August 2022, inter alia, duly approved/took on record the following: ? Unaudited Standalone Financial Results and Unaudited Consolidated Financial Results for the quarter ended 30 June 2022; ? Declaration of interim dividend of Rs. 7.35/- (at the rate of 735%) on each fully paid-up equity share of Re. 1/- for the Financial Year 2022-2023; ? Further, as Communicated in our intimation letter dated 02 August 2022, the record date for determining the eligibility of shareholders for the payment of the interim dividend has been fixed as 16 August 2022. The payment of interim dividend would be made to the eligible shareholders on or before 04 September 2022. The Board Meeting commenced at 11:00 A.M. and concluded at 12:35 P.M. Kindly take the above information on your records.
05-08-2022
Bigul

Eris Lifesciences Ltd - 540596 - Board declares Interim Dividend

 Eris Lifesciences Ltd has informed BSE that the Board of Directors of the Company, in their meeting held on August 05, 2022, inter alia, approved/took on record the following :- Declaration of interim dividend of Rs. 7.35/- (at the rate of 735%) on each fully paid-up equity share of Re. 1/- for the Financial Year 2022-2023.
05-08-2022
Bigul

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Pursuant to the requirement of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached the investor presentation made by the Company.
05-08-2022
Bigul

Eris Lifesciences Ltd - 540596 - Board Meeting Outcome for OUTCOME OF THE BOARD MEETING

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e., 05 August 2022, inter alia, duly approved/took on record the following: ? Unaudited Standalone Financial Results and Unaudited Consolidated Financial Results for the quarter ended 30 June 2022; ? Declaration of interim dividend of Rs. 7.35/- (at the rate of 735%) on each fully paid-up equity share of Re. 1/- for the Financial Year 2022-2023; ? Further, as Communicated in our intimation letter dated 02 August 2022, the record date for determining the eligibility of shareholders for the payment of the interim dividend has been fixed as 16 August 2022. The payment of interim dividend would be made to the eligible shareholders on or before 04 September 2022.
05-08-2022
Bigul

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Dear Sir/Madam, Pursuant to the General Circular No. 20/2020 dated 05th May 2020, issued by the Ministry of Corporate Affairs and pursuant to the applicable provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the copies of the newspaper clippings regarding the Public Notice of the Sixteenth Annual General Meeting of the Company published in Financial Express (both English and Gujarati) on Tuesday, 02 August 2022. This is for your information and record.
02-08-2022
Bigul

Eris Lifesciences Ltd - 540596 - Interim Dividend

 Dear Sir / Madam, It is hereby informed that the Board of Directors shall consider the declaration of interim dividend for the Financial Year 2022-23 at its meeting which is scheduled to be held on 05 August 2022. In the event of the declaration of interim dividend as aforesaid, the proposed record date for the purpose of determining the members eligible for receiving the said interim dividend shall be 16 August 2022.
02-08-2022
Bigul

Eris Lifesciences Ltd - 540596 - Update on board meeting

 Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2022 ,inter alia, to consider and approve Update on board meeting
02-08-2022
Bigul

Eris Lifesciences Ltd - 540596 - Corporate Action-Board to consider Dividend

 Dear Sir / Madam, It is hereby informed that the Board of Directors shall consider the declaration of interim dividend for the Financial Year 2022-23 at its meeting which is scheduled to be held on 05 August 2022. In the event of the declaration of interim dividend as aforesaid, the proposed record date for the purpose of determining the members eligible for receiving the said interim dividend shall be 16 August 2022.
02-08-2022
Next Page
Close

Let's Open Free Demat Account